Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Pick the Right Material Organization: Fundamental Tips - 2Private sector revives the climate disaster database Trump tried to squash
- 3The race to mine the moon is on – and it urgently needs some clear international rules
- 4How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- 5Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- UB professor shares his experience on almost becoming an astronaut
- Shipping: The Corridors of Trade and the Coming of Another Period
- How to get tickets to Jay-Z’s sold out Yankee Stadium shows
- A Timeline of Rising Antisemitism in Australia
- Charlotte faith leaders hold interfaith forum on Black and Palestinian solidarity
- The Forgotten BMW Coupe That Turned a 5 Series Into Something Far More Exotic
- CDC clarifies stance on vaccines and autism, stating no evidence supports the link
